Clinical Trial Update: Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on adoptive BCMA CAR-NK cells for relapsed/refractory multiple myeloma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• adoptive BCMA CAR-NK cells (BCMA CAR-NK cells)

Snippet

Sponsor: Asclepius Technology Company Group (Suzhou) Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN